Report #2831283

Received Mar 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 71 yrs
State: KS
Recovered: Unknown
Vaccinated: Feb 22, 2025
Onset: Feb 22, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPAB	HEP A + HEP B (TWINRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	M4B34	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

HCP gave 2nd dose on 22-Feb-2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 71-year-old male patient who received HAB (Twinrix adult) (batch number M4B34, expiry date 28-SEP-2026) for prophylaxis. Previously administered products included Twinrix adult (got his first shot on 14-JUNE-2024). On 22-FEB-2025, the patient received the 2nd dose of Twinrix adult. On 22-FEB-2025, an unknown time after receiving Twinrix adult, the patient experienced drug dose administration interval too long (Verbatim: HCP gave 2nd dose on 22-Feb-2025). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 07-MAR-2025 The patient received 2nd dose of Twinrix adult, later than the recommended interval, which led to lengthening of vaccination schedule.